Delta-like protein 3 (DLL3) Targeted Therapeutics

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: Word Table
Product Line: Target Pipeline List
Product Code: LMTPL035
Release Date: January of 2019
Loading...

Delta-like protein 3 (DLL3) Targeted Therapeutics – Target Pipeline List

Target: Delta-like canonical Notch ligand 3; delta-like protein 3; DLL3;; scr-like kinase Fyn3; SC-16

This Target Pipeline list provides an overview of antibody- and cell-based therapeutics targeting DLL3 in development for treatment of DLL3-overexpressing cancers.

Upregulated delta-like protein 3 (DLL3) functions as a Notch ligand and has been a target for cancer therapy. DLL3 is fundamental in the downstream cellular signaling for proliferation and apoptosis. DLL3 is an atypical member of the Notch receptor ligand family that is able to inhibit activation of the Notch receptors. DLL3 contains different functional domains (such as a Delta-Serrate-Lag2 [DSL] domain, epidermal growth factor [EGF] repeats, and a transmembrane domain). Aberrant DLL3 expression has been found in neuroendocrine cancers and high-grade serous ovarian cancer.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.